Kailera Therapeutics, Inc. Restricted Cash and Cash Equivalents
Kailera Therapeutics, Inc. (KLRA) had Restricted Cash and Cash Equivalents of $761.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-12
- 2026-06-30: Restricted Cash and Cash Equivalents $761.00K.
- 2026-03-31: Restricted Cash and Cash Equivalents $761.00K.
- 2025-06-30: Restricted Cash and Cash Equivalents $761.00K.
- 2025-03-31: Restricted Cash and Cash Equivalents $761.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $761.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $761.00K 10-Q · filed 2026-05-26 |
| 2025-06-30 | $761.00K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $761.00K 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |